---
layout: default
title: Tenofovir Alafenamide
description: "Tenofovir Alafenamide çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 3 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 164
evidence_level: L3
indication_count: 3
---

# Tenofovir Alafenamide

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>3</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Tenofovir Alafenamide è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Tenofovir Alafenamide å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Tenofovir alafenamideï¼ˆéŸ‹ç«‹å¾—ï¼‰æ˜¯æ ¸è‹·é…¸åè½‰éŒ„é…¶æŠ‘åˆ¶åŠ‘ï¼Œé™¤ç¾æœ‰ HIV/HBV é©æ‡‰ç—‡å¤–ï¼ŒTxGNN é æ¸¬å…¶å° SIV æ„ŸæŸ“å…·æ½›åŠ›ï¼Œå·²æœ‰è‡¨åºŠè©¦é©—åŠæ–‡ç»æ”¯æŒã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Tenofovir alafenamide (TAF) |
| DrugBank ID | DB09299 |
| å°ç£å•†å“å | éŸ‹ç«‹å¾—è†œè¡£éŒ ã€é”å¯æ®è†œè¡£éŒ ã€å¿…å…‹é”è†œè¡£éŒ ç­‰ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | HIV-1 æ„ŸæŸ“æ²»ç™‚ã€HIV æš´éœ²å‰é é˜² (PrEP)ã€æ…¢æ€§ B å‹è‚ç‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | SIV æ„ŸæŸ“ã€è²“æ„›æ»‹ç—…ã€ç¥ç¶“ç™¼è‚²éšœç¤™ |
| æœ€é«˜è­‰æ“šç­‰ç´š | **L2**ï¼ˆå–®ä¸€ RCT / å¤šå€‹ Phase 2ï¼‰ |
| TxGNN åˆ†æ•¸ | 0.875ï¼ˆSIV æ„ŸæŸ“ï¼‰ |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. feline acquired immunodeficiency syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>### ä½œç”¨æ©Ÿè½‰æ”¯æŒ</p>

<p>Tenofovir alafenamide æ˜¯ tenofovir çš„å‰é©…è—¥ç‰©ï¼Œé€éæŠ‘åˆ¶åè½‰éŒ„é…¶é˜»æ–·ç—…æ¯’è¤‡è£½ã€‚å…¶æ©Ÿè½‰å°æ‰€æœ‰ä¾è³´åè½‰éŒ„é…¶çš„é€†è½‰éŒ„ç—…æ¯’ï¼ˆåŒ…æ‹¬ HIVã€SIVã€FIVï¼‰ç†è«–ä¸Šå‡æœ‰æ•ˆã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. simian immunodeficiency virus infection</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03577782" target="_blank">NCT03577782</a></td><td>PHASE1, PHASE2</td><td>UNKNOWN</td><td>12</td><td>Phase II Clinical Trial to Analyze the Safety and Efficacy of Vedolizumab Combin...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ9 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38134382/" target="_blank">38134382</a></td><td>2024</td><td>Article</td><td>The Journal of infectious dise</td><td>Extended Postexposure Protection Against Vaginal Simian/Human Immunodeficiency V...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31362305/" target="_blank">31362305</a></td><td>2019</td><td>Article</td><td>The Journal of infectious dise</td><td>Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27465645/" target="_blank">27465645</a></td><td>2016</td><td>Article</td><td>The Journal of infectious dise</td><td>Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination P...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35913838/" target="_blank">35913838</a></td><td>2022</td><td>Article</td><td>The Journal of antimicrobial c</td><td>Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide f...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39632836/" target="_blank">39632836</a></td><td>2024</td><td>Article</td><td>Nature communications</td><td>SHIV remission in macaques with early treatment initiation and ultra long-lastin...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16810108/" target="_blank">16810108</a></td><td>2006</td><td>Article</td><td>Journal of acquired immune def</td><td>Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22740713/" target="_blank">22740713</a></td><td>2012</td><td>Article</td><td>The Journal of infectious dise</td><td>Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31730629/" target="_blank">31730629</a></td><td>2019</td><td>Article</td><td>PloS one</td><td>Training rhesus macaques to take daily oral antiretroviral therapy for preclinic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39559349/" target="_blank">39559349</a></td><td>2024</td><td>Article</td><td>Frontiers in immunology</td><td>A dual-purpose humanized mouse model for testing antiviral strategies against bo...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.87%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

### å·²æ ¸å‡†ç”¢å“ï¼ˆå…± 13 é …ï¼‰

| è¨±å¯è­‰è™Ÿ | å•†å“å | æˆåˆ†çµ„åˆ | é©æ‡‰ç—‡ |
|----------|--------|----------|--------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027163è™Ÿ | éŸ‹ç«‹å¾—è†œè¡£éŒ  25 æ¯«å…‹ | TAF å–®æ–¹ | æ…¢æ€§ B å‹è‚ç‚ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027012è™Ÿ | é”å¯æ®è†œè¡£éŒ  | Emtricitabine + TAF | HIV PrEP |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027398è™Ÿ | å¿…å…‹é”è†œè¡£éŒ  | Bictegravir + Emtricitabine + TAF | HIV æ²»ç™‚ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027464è™Ÿ | èˆ’ç™¼æ³°è†œè¡£éŒ  | Emtricitabine + TAF | HIV æ²»ç™‚ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027645è™Ÿ | æ¬£ä»–ä½³è†œè¡£éŒ  | Darunavir + Cobicistat + Emtricitabine + TAF | HIV æ²»ç™‚ |

### å¥ä¿çµ¦ä»˜ç‹€æ…‹

ä¸»è¦è¤‡æ–¹ç”¢å“å‡æœ‰å¥ä¿çµ¦ä»˜ï¼Œå–®æ–¹éŸ‹ç«‹å¾—ç”¨æ–¼ B è‚æ²»ç™‚äº¦æœ‰çµ¦ä»˜ã€‚

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | èªªæ˜ |
|--------------|----------|------|
| TAS2R39 ç›¸é—œè—¥ç‰© | è¼•åº¦ | è‹¦å‘³å—é«”äº¤äº’ä½œç”¨ï¼Œè‡¨åºŠæ„ç¾©ä¸æ˜ |

### ä¸»è¦ä¸è‰¯åæ‡‰

- è…åŠŸèƒ½å½±éŸ¿ï¼ˆè¼ƒèˆŠå‹ TDF æ”¹å–„ï¼‰
- éª¨å¯†åº¦ä¸‹é™ï¼ˆè¼ƒèˆŠå‹ TDF æ”¹å–„ï¼‰
- é ­ç—›ã€å™å¿ƒã€è…¹ç€‰

### ç‰¹æ®Šæ—ç¾¤æ³¨æ„äº‹é …

- è…åŠŸèƒ½ä¸å…¨ï¼šeGFR < 15 éœ€è¬¹æ…
- æ‡·å­•ï¼šCategory Bï¼Œæ¬Šè¡¡åˆ©å¼Š


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Bone Diseases** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šIn clinical trials, tenofovir disoproxil fumarate (DF) was associated with slightly greater reductions in bone mineral density (BMD) and increases in ...

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é€šå¸¸ç„¡éœ€èª¿æ•´åŠ‘é‡ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é€šå¸¸ç„¡éœ€èª¿æ•´åŠ‘é‡ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Hepatitis B** ğŸŸ¢ Minor
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚é¢¨éšªåŒ…æ‹¬ï¼šè‚æ¯’æ€§ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬å¯ä¿¡åº¦è©•ä¼°

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | å¯ä¿¡åº¦ | å»ºè­° |
|------------|----------|--------|------|
| SIV æ„ŸæŸ“ | L2 | é«˜ | ä¸»è¦ä½œç‚ºç ”ç©¶æ¨¡å‹ï¼Œéäººé¡æ²»ç™‚ç”¨é€” |
| è²“æ„›æ»‹ç—… | L4 | ä¸­ | ç¸é†«é ˜åŸŸå¯é€²ä¸€æ­¥ç ”ç©¶ |
| ç¥ç¶“ç™¼è‚²éšœç¤™ | L5 | ä½ | æ©Ÿè½‰é—œè¯ä¸æ˜ç¢º |

### è‡¨åºŠæ‡‰ç”¨å»ºè­°

1. **SIV æ„ŸæŸ“**ï¼šå·²æœ‰å……åˆ†å‹•ç‰©æ¨¡å‹æ•¸æ“šï¼Œé©åˆä½œç‚º HIV ç ”ç©¶çš„è½‰è­¯å¹³å°
2. **è²“æ„›æ»‹ç—…**ï¼šå¯è€ƒæ…®ç¸é†«è‡¨åºŠè©¦é©—
3. **ç¥ç¶“ç™¼è‚²éšœç¤™**ï¼šç›®å‰è­‰æ“šä¸è¶³ï¼Œä¸å»ºè­°è‡¨åºŠæ‡‰ç”¨

### å¾ŒçºŒç ”ç©¶æ–¹å‘

- é•·æ•ˆ TAF è£½åŠ‘åœ¨ HIV PrEP çš„è‡¨åºŠæ‡‰ç”¨
- ç¸é†«é ˜åŸŸ FIV æ²»ç™‚çš„å¯è¡Œæ€§è©•ä¼°

---

*æœ¬ç­†è¨˜ç”± TxGNN é æ¸¬ç³»çµ±ç”¢ç”Ÿï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*
*æ›´æ–°æ—¥æœŸï¼š2026-02-11*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Avelumab]({{ "/drugs/avelumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cobicistat]({{ "/drugs/cobicistat/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Polyethylene Glycol 400]({{ "/drugs/polyethylene_glycol_400/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Oxybutynin]({{ "/drugs/oxybutynin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Caspofungin]({{ "/drugs/caspofungin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Tenofovir Alafenamideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/tenofovir_alafenamide/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_tenofovir_alafenamide,
  title = {Tenofovir Alafenamideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/tenofovir_alafenamide/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
